Physical Restraints in Intensive Care Unit Patients
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Jun 30, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of physical restraints in patients who are critically ill and being treated in the Intensive Care Unit (ICU). Physical restraints are sometimes used to keep patients safe, especially if they might accidentally pull out important medical devices like IV lines. However, these restraints can also lead to feelings of confusion and agitation. To address this, researchers have developed a decision-making tool that helps healthcare providers decide when it is appropriate to use restraints, based on objective assessments of a patient’s mental state.
To be eligible for this study, participants must be over 18 years old and have been in the ICU for at least 48 hours. They need to agree to participate, or their family member or trusted person can provide consent on their behalf. Throughout the study, participants can expect careful monitoring and support as the team evaluates the effectiveness of the new decision-making tool. This trial aims to improve patient care by reducing unnecessary use of restraints and enhancing safety in the ICU.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient, male or female, over 18 years of age, hospitalized in ICU for at least 48 hours.
- • Consent to participate in the patient's study or authorization to carry out the research collected from the designated trustworthy person (failing this, a family member, or failing this, a close and stable relation with the person concerned) according to the modalities described in Title II of the book of the First Public Health Code. If no relative is present, the patient may be included on the advice of the investigator (article L. 1111-6). A consent form for continuation of the study and use of the data will then be signed by the patient if and when the patient is again conscious and lucid, or if the patient is unable to express consent, authorization to continue the research will be obtained from the designated trusted person.
- • Patient covered by a social security system.
- Exclusion Criteria:
- • Predictable and uninterrupted maintenance of deep sedation throughout the duration of the stay, due to the seriousness of the lesions, from the moment the patient is admitted to the intensive care unit.
- • Lack of predictable remission of a severe coma present on admission to intensive care.
- • Refusal to participate by the patient, or by the trusted person contacted by default.
- • Patient with DNR (do not resuscitate) orders.
- • Patient under legal protection.
- • Patient already included in the protocol during another stay in resuscitation
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Annecy, , France
Clermont Ferrand, , France
Paris, , France
Montpellier, , France
Aurillac, , France
Nice, , France
Belfort, , France
Dijon, , France
Strasbourg, , France
Saint Malo, , France
Avignon, , France
Cergy Pontoise, , France
Clermont Ferrand, , France
Lyon, , France
Marseille, , France
Marseille, , France
Montluçon, , France
Poissy, , France
Rodez, , France
Saint étienne, , France
Salon De Provence, , France
Vichy, , France
Le Puy En Velay, , France
Moulins, , France
Strasbourg, , France
Strasbourg, , France
Patients applied
Trial Officials
Périne Vidal
Principal Investigator
CHU de Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials